Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00408447 · ClinicalTrials.gov registry record · Phase 2
Stem Cell Transplant in Sickle Cell Disease and Thalassemia
A Phase 2 study of Sickle Cell Disease and Beta-Thalassemia, sponsored by Columbia University.
- Active
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 1
- Study location
NCT00408447 is a Phase 2 study of Sickle Cell Disease and Beta-Thalassemia that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 53 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00408447, a Phase 2 study of Sickle Cell Disease and Beta-Thalassemia, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately ablative) will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease. Patients will receive a chemotherapy regimen with busulfan, fludarabine, and alemtuzumab followed by an infusion of stem cells, either from a family-related or cord-blood matched donor.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Busulfan
- DRUG Alemtuzumab
- PROCEDURE Allogeneic stem cell transplant
Study Locations (1)
New York
- Morgan Stanley Children's Hospital, New York-Presbyterian, Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2004-09 |
| Est. Completion | 2025-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00408447
The ClinicalTrials.gov registry entry for NCT00408447 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (82% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 4 interventions - of which Fludarabine is the first listed.
NCT00408447 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00408447 about?
NCT00408447 is a clinical study titled "Stem Cell Transplant in Sickle Cell Disease and Thalassemia". The primary purpose of this study is to see if giving lower doses of chemotherapy (moderately ablative) will result in successful bone marrow replacement without as severe side-effects but with permanent control of the disease. Patients will receive a chemotherapy regimen with busulfan, fludarabine,...
What is the current status of trial NCT00408447?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2004-09. Estimated completion is 2025-02.
What conditions does trial NCT00408447 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Beta-Thalassemia.
What interventions are being tested in trial NCT00408447?
The interventions under investigation include: Fludarabine (DRUG), Busulfan (DRUG), Alemtuzumab (DRUG), Allogeneic stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT00408447?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00408447 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.